Senzime AB (publ) represents values of innovation, quality, and patient safety. As a leading medical technology company, Senzime is dedicated to improving healthcare by providing advanced monitoring solutions. The company focuses on developing innovative products that enhance the accuracy and reliability of patient data, enabling healthcare professionals to make informed decisions. Senzime's corporate philosophy revolves around a patient-centric approach, ensuring the highest level of care and safety for individuals undergoing surgery or other medical procedures. With a strong commitment to excellence and a focus on improving patient outcomes, Senzime AB (publ) is a trusted name in the medical technology industry.

Senzime AB (publ) is primarily present in various countries and regions globally. The company has a strong presence in Europe, including Sweden, Germany, France, and the United Kingdom. Additionally, Senzime has expanded its reach to other parts of the world, including the United States, China, Japan, and several countries in the Middle East. With its growing international presence, Senzime AB (publ) aims to offer its innovative medical technology solutions and products to healthcare providers and patients worldwide.

Senzime AB (publ) has achieved several significant milestones. The company successfully launched the TetraGraph® monitoring system, a pioneering device for neuromuscular monitoring. Senzime AB (publ) has also gained regulatory approvals for the TetraGraph® system in various markets, including the European Union and the United States. Moreover, they have secured partnerships and collaborations with leading medical institutions to enhance the adoption of their innovative technologies. In addition, Senzime AB (publ) has received prestigious awards and recognitions for their groundbreaking solutions in the field of patient monitoring. These milestones demonstrate the company's commitment to revolutionizing healthcare through advanced and effective medical devices.

Senzime AB (publ) is a Swedish medical technology company founded in 2010. Specializing in patient monitoring solutions, the company focuses on improving clinical outcomes and enhancing healthcare efficiency. Senzime AB (publ) offers innovative products such as TetraGraph, a neuromuscular monitoring system, and OnZurf, a continuous glucose monitoring system. With a strong commitment to research and development, Senzime AB (publ) has evolved into a leading provider of advanced medical devices globally. Their cutting-edge technology and dedication to improving patient care have positioned Senzime AB (publ) as a reliable and trusted name in the healthcare industry.

Senzime AB (publ) faces competition in the market from various companies. Some of the main competitors of Senzime AB (publ) include Medtronic, GE Healthcare, Philips Healthcare, and Masimo Corporation. These companies also provide innovative medical devices and solutions for patient monitoring and anesthesia. Senzime AB (publ) competes by offering its unique product portfolio, including the TetraGraph neuromuscular monitoring system, which provides accurate and reliable data for monitoring patients' response to anesthesia. The company's focus on advancing patient safety and enhancing surgical outcomes sets them apart from their competitors in the market.

Senzime AB (publ) is primarily active in the medical technology industry.

The business model of Senzime AB (publ) is focused on the development and commercialization of medical technology products for monitoring patients during surgeries. Senzime offers innovative solutions that enable healthcare professionals to accurately assess and manage patients' physiological responses in real-time, providing valuable data for improved patient care and outcomes. Senzime's flagship product is the TetraGraph, a neuromuscular monitoring system that helps in measuring the patient's muscle function and depth of blockade during anesthesia. By delivering advanced monitoring solutions, Senzime aims to enhance patient safety and optimize anesthesia management in healthcare settings.

Senzime AB (publ) KGV yra −8,14.

Senzime AB (publ) KUV yra 9,95.

AlleAktien kokybės įvertis Senzime AB (publ) yra 7/10.

tikėtina Senzime AB (publ) pardavimai yra 75,48 mln. SEK.

tikėtina Senzime AB (publ) pelnas yra −92,32 mln. SEK.

Senzime AB (publ) is a Swedish medical technology company that focuses on innovative systems for monitoring anesthesia and postoperative stress in patients. It was founded in 2008 and is headquartered in Uppsala. The company's business model focuses on the development, manufacturing, and marketing of medical products that aim to meet the clinical need for improved monitoring systems. Senzime currently offers two main products: the TetraGraph® system and the CliniSenz® system. The TetraGraph® system is a non-invasive monitoring system that monitors the neuromuscular blockade state of patients during anesthesia using electromyographic signals (EMG). The system monitors the patient's muscle activity to determine the timing of extubation and enable a more effective and safe removal of ventilation devices. The TetraGraph system can also be used to avoid potential muscle overstimulation from surgical devices that may harm the lungs or respiratory muscles. The CliniSenz® system is a non-invasive system for monitoring the body's postoperative stress. It consists of a bioelectrical sensor attached to the patient's skin that continuously monitors electromyographic signals, heart rate, and blood oxygen levels. By monitoring these parameters, doctors can determine the best time to administer pain medication or start rehabilitation. Monitoring heart rate can also help doctors identify if the patient is experiencing overload and adjust treatment accordingly. Senzime has a unique business strategy based on partnerships with leading hospital chains, anesthesiologists, and intensive care physicians worldwide, as well as collaboration with other companies in the field of medical device development and marketing. Its goal is to sell the TetraGraph and CliniSenz systems in both Europe and the United States and increase market share by focusing on hospitals and clinics. The company is committed to expanding its technology into other areas of healthcare by investing in research and development of new products. It is seeking marketing and distribution partners to sell its products globally and raise brand awareness. The focus is on developing innovative medical devices that can contribute to more efficient healthcare and provide better patient care. In summary, Senzime relies on innovative technologies to improve patient monitoring during and after surgery. Its business model focuses on the development and marketing of medical products through partnerships with leading hospitals and clinic chains. The company has a unique position in the market and continues to invest in the development of new products.

Senzime AB (publ) moka dividendą 0 SEK, kuris yra paskirstytas per išmokas per metus.

Dividenda šiuo metu negali būti apskaičiuota Senzime AB (publ) arba įmonė dividendų nemoka.

Senzime AB (publ) ISIN yra SE0002478776.

Senzime AB (publ) WKN yra A0X93V.

Senzime AB (publ) akcijų simbolis yra SEZI.ST.

Per paskutinius 12 mėnesių Senzime AB (publ) išmokėjo dividendą, kurios dydis siekė . Tai atitinka maždaug dividendų grąžą. Artimiausiems 12 mėnesiams Senzime AB (publ) tikėtina išmokės dividendus, kurie sudarys 0 SEK.

Senzime AB (publ) šiuo metu yra dydžio dividendų grąža.

Senzime AB (publ) moka dividendus kas ketvirtį. Jie išmokami mėnesiais.

Senzime AB (publ) per paskutiniuosius 0 metus kiekvienais metais mokėjo dividendus.

Artimiausiems 12 mėnesiams tikimasi dividendų, kurių dydis yra 0 SEK. Tai atitinka 0 % dividendų grąžos procentą.

Senzime AB (publ) priskiriamas sektoriui "Sveikata".

Norėdamas gauti paskutinį Senzime AB (publ) dividendą nuo 2024-08-03, kurio dydis yra 0 SEK, turėjai turėti akciją savo depozite prieš ex-dieną, kuri buvo 2024-08-03.

Paskutinės dividendų išmokėjimas įvyko 2024-08-03.

2023 metais Senzime AB (publ) išmokėjo 0 SEK dividendų.

Senzime AB (publ) dividendai yra mokami SEK.